BioWorld3d
First-in-class dual-payload anti-HER2 agent presented
Anti-HER2 antibody-drug conjugates (ADCs) have proven effective in multiple tumor types. However, between 64% and 85% of HER2+ breast and gastric cancer patients retain HER2 expression after treatment ...
Case study describes potential breakthrough in treatment of aggressive type of prostate cancer
Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case ...
Targeted Oncology9d
Advances in Treating HER2+ Breast Cancer With Brain Metastases
Sarah Sammons, MD, discusses findings from an analysis of the DESTINY-Breast03 trial regarding trastuzumab deruxtecan vs ...
Targeted Oncology10d
FDA's October 2024 Highlights: Advancing Treatments in Oncology
The FDA approved zolbetuximab (Vyloy) on October 18, 2024, as a first-line treatment for locally advanced unresectable or ...
Infobae14d
Trastuzumab Deruxtecan
Resultados del ensayo clínico DESTINY-06 demuestran que el anticuerpo conjugado trastuzumab deruxtecan mejora la supervivencia en pacientes con cáncer de mama metastásico RH+ y baja expresión ...
The Jamaica Observer29d
HIC launches Masters of Medicine Conference with exclusive screening of The M Factor, highlighting women’s health and menopause awareness
THE Heart Institute of the Caribbean (HIC) is excited to announce the upcoming Masters of Medicine Conference, set for January 2025. In recognition of World Menopause Day on October 18 ...